This narrative review focuses on a recent Food and Drug Administration (FDA) approved class of hypoglycemic drugs known as SGLT2 inhibitors (SGLT2i) to treat diabetes mellitus (DM) in cats. This evidence concerns the gene SLC5A2 and diabetes mellitus.